Journal
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
Volume 71, Issue -, Pages 1327-1341Publisher
ELSEVIER
DOI: 10.1016/j.msec.2016.11.073
Keywords
Liposome; Co-delivery; Combination therapy; Chemotherapy; Cancer treatment
Categories
Funding
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Ask authors/readers for more resources
Combination therapy and nanotechnology offer a promising therapeutic method in cancer treatment. By improving drug's pharmacoldnetics, nanoparticulate systems increase the drug's therapeutic effects while decreasing its adverse side effects related to high dosage. Liposomes are extensively used as drug delivery systems and several liposomal nanomedicines have been approved for clinical applications. In this regard, liposome-based combination chemotherapy (LCC) opens a novel avenue in drug delivery research and has increasingly become a significant approach in clinical cancer treatment This review paper focuses on LCC strategies including co-delivery of: two chemotherapeutic drugs, chemotherapeutic agent with anti-cancer metals, and chemotherapeutic agent with gene agents and ligand-targeted liposome for co-delivery of chemotherapeutic agents. Definitely, the multidisciplinary method may help improve the efficacy of cancer therapy. An extensive literature review was performed mainly using PubMed. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available